Hikma Pharmaceuticals PLC : The bullish trend is not over
Entry price | Target | Stop-loss | Potential |
---|
GBX 1,073 |
GBX 0 |
GBX 1,046 |
-100% |
---|
Hikma Pharmaceuticals has still an uptrend and is going toward its highest level.
The company shows strong fundamentals. The growth prospective is encouraging as shown by the revenues expected to almost double in the next 5 years. In addition, the consensus revised upward EPS estimates for this year and that let see a great potential for the security on the stock market.
From a technical viewpoint, the security is trading in a bullish trend in the short and the long term. Increasing moving averages let think there will be no reversal in the coming trading sessions. This growth should help to breakout soon the GBp 1087 medium term resistance in order to reach the trend line.
A long position can be open at the current prices to target GBp 1150 in the next weeks. A stop loss will be placed below GBp 1050.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.